Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.

Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel ( = 162) versus cilta-cel ( = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS).

The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas.

The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease. Herein, we review and discuss the standard-of-care products and indications for mosunetuzumab, epcoritamab, and glofitamab. We provide a detailed overview of the registrational clinical trials, as well as a review of ongoing trials and likely future indications.

Thermal Behavior of -Octanol and Related Ether Alcohols.

The thermal behavior of -octanol and related ether alcohols has been studied by differential scanning calorimetry (DSC). The melting point, heat of fusion, and isobaric heat capacities of -octanol obtained from the DSC measurements are in good agreement with literature values. The ether alcohols display kinetic barriers for forming a solid phase during cooldown.

Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.

The naturally occurring mutation E484D in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can render viral entry ACE2 independent and imdevimab resistant. Here, we investigated whether the cellular proteins ASGR1, DC-SIGN, and TMEM106B, which interact with the viral S protein, can contribute to these processes. Employing S protein-pseudotyped particles, we found that expression of ASGR1 or DC-SIGN jointly with TMEM106B allowed for robust entry of mutant E484D into otherwise non-susceptible cells, while this effect was not observed upon separate expression of the single proteins and upon infection with SARS-CoV-2 wild type (WT).

The utility of the Living Planet Index as a policy tool and for measuring nature recovery.

The Living Planet Index (LPI) is a leading global biodiversity indicator based on vertebrate population time series. Since it was first developed over 25 years ago, the LPI has been widely used to indicate trends in biodiversity globally, primarily reported every two years in the Living Planet Report. Based on relative abundance, a sensitive metric of biodiversity change, the LPI has also been applied as a tool for informing policy and used in assessments for several multilateral conventions and agreements, including the Convention on Biological Diversity 2010 Biodiversity Target and Aichi targets.